GENETIC RESISTANCE TO HIV
=========================

Infection with human immunodeficiency virus-1 (HIV-1) remains a major cause of premature death worldwide. In order to enter and infect immune cells, HIV-1 binds to cell surface receptors including the CCR5 chemokine receptor ([Fig. 1](#eov016-F1){ref-type="fig"}A). A well-described functional polymorphism in the *CCR5* gene comprises a 32-bp deletion (called *CCR5-Δ32)* which results in a lack of the last three transmembrane domains of the CCR5 protein \[[@eov016-B1]\]. The mutated protein is contained in the cytoplasm, resulting in a complete lack of CCR5 cell surface receptor. In the absence of this co-receptor binding site, HIV-1 is unable to enter the cell ([Fig. 1](#eov016-F1){ref-type="fig"}B); individuals homozygous for *CCR5-Δ32* display complete resistance to HIV-1, whereas heterozygotes have a delayed onset of AIDS \[[@eov016-B1]\].
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EVOLUTIONARY PERSPECTIVES
=========================

Chemokines and their receptors play a central role in the trafficking and activation of lymphocytes, but perhaps surprisingly there are no apparent pathological consequences of *CCR5-Δ32* homozygosity. Intriguingly, this variant displays marked population differentiation which would not be explained by the very recent emergence of HIV-1 in sub-Saharan Africa: the *CCR5-Δ32* allele is highly prevalent in Europeans (frequency up to 14%), while very rare or absent among African and Asian populations \[[@eov016-B2]\].

Early studies suggested that the *CCR5-Δ32* allele arose relatively recently (∼700 years ago) and was subject to strong positive selection \[[@eov016-B2]\]. Infection with *Yersinia pestis*---the cause of the bubonic plague in Europe during this time period---or smallpox were suggested as potential selective factors favoring *CCR5-Δ32* \[[@eov016-B2]\]. HIV and smallpox both cause cellular immune dysfunction and both enter leukocytes using chemokine receptors. If exposure to smallpox provided selective pressure favoring *CCR5-Δ32*, it is plausible that exposed populations now have an evolutionary advantage in facing HIV \[[@eov016-B3]\]. Recently, however, high-density genetic maps have questioned the evidence for a recent origin of *CCR5-Δ32*, suggesting instead that this allele may have arisen ∼5000 years ago \[[@eov016-B4]\], under neutral evolution, or subject to an ancient, currently unknown positive selective pressure.

FUTURE IMPLICATIONS
===================

Antagonism of CCR5 interferes with HIV-1 cell entry, and indeed the CCR5 antagonist drug maraviroc is approved by the FDA for treatment of exclusively CCR5-tropic viral strains of HIV-1 \[[@eov016-B5]\]. The clinical relevance of *CCR5-Δ32* is further illustrated by a case of long-term HIV control following stem-cell transplantation from a *CCR5-Δ32* homozygous donor \[[@eov016-B6]\], although viral escape through chemokine receptors other than CCR5 may limit the success of this approach \[[@eov016-B7]\]. Of broader relevance, development of a therapy that eliminates the transmembrane portion of the CCR5 protein to mimic the advantage conferred by the natural *CCR5-Δ32* variant might constitute a functional HIV-1 cure. A 'gene editing' approach using infusion of autologous CD4 T cells which have been modified by zinc finger nucleases to disrupt *CCR5* (mimicking *CCR5-Δ32*) appears safe and confers partial disease resistance \[[@eov016-B8]\].
